Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 5/20 | 0.76 |
| ▸ | RAB9A | P51151 | 9/20 | 0.75 |
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.75 |
| ▸ | NPC1 | O15118 | 6/20 | 0.75 |
| ▸ | AHR | P35869 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 8/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421217 | 0.89 | RAB9A (0.73) | DHODHRAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL479877 | 0.86 | DHODH (1.00) | DHODHRAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL28816740 | 0.86 | DHODH (0.81) | DHODHRAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL28824955 | 0.86 | RAB9A (1.00) | DHODHRAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL29898323 | 0.86 | RAB9A (0.76) | DHODHRAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL28824933 | 0.86 | RAB9A (0.76) | DHODHRAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL29898269 | 0.86 | RAB9A (1.00) | DHODHRAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL2714517 | 0.86 | MAPT (0.65) | DHODHRAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL29421237 | 0.86 | MAPT (0.65) | DHODHRAB9AMAPTSMN1; SMN2NPC1 | |
| SCHEMBL5217337 | 0.84 | MEN1 (0.75) | DHODHRAB9AMAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | claimed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | claimed |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-03-16 | — | — | US | claimed |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2019-04-25 | — | — | US | claimed |
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-12-14 | — | — | US | claimed |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO LTD (KR) | 2017-03-09 | — | — | US | claimed |
| JP-56164189-A | — | — | None | — | — | JP | disclosed |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| CN-116574053-A | RIPK1 kinase target inhibitor and medical application thereof | 中国药科大学 | 2023-08-11 | — | — | CN | disclosed |
| CN-114989079-B | RIPK1 kinase target inhibitor and medical application thereof | 中国药科大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| CN-114989079-A | RIPK1 kinase target inhibitor and medical application thereof | 中国药科大学 | 2022-09-02 | — | — | CN | disclosed |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-03-16 | — | — | US | disclosed |
| CN-1040327-C | Optionally substituted pyrido [2,3-d] pyrimidine-2,4(1H,3H)-diones and pyrido [2,3-d] pyrimidine-2(1H,3H)-ones | SYNTEX INC (US) | 1998-10-21 | — | — | CN | disclosed |
| EP-0631580-A1 | PYRIDO 2,3-d]PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-01-04 | — | — | EP | disclosed |
| US-5264437-A | Antiinflammatory agents, immunosuppressants or antiallergens | SYNTEX (U.S.A.) INC. (US) | 1993-11-23 | — | — | US | disclosed |
| CN-1078470-A | Any pyrido [2, the 3-d] pyrimidine-2 that replaces, 4-(1H, 3H)-two ketone and pyrido [2,3-d] pyrimidine-2 (1H, 3H)-ketone | SYNTEX A INC (US) | 1993-11-17 | — | — | CN | disclosed |
| WO-1993019068-A1 | PYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1993-09-30 | — | — | WO | disclosed |
| JP-S56164189-A | PREPARATION OF NOVEL PYRIDO 2,3-D PYRIMIDINE-2-THIONE DERIVATIVE | HISAMITSU PHARMACEUT CO INC | 1981-12-17 | — | — | JP | disclosed |
| US-4009166-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, CNS DEPRESSANTS | HISAMITSU PHARMACEUTICAL CO., INC. (JA) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355690-A9 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | DHODH 2325/4885RAB9A 1486/4885MAPT 498/4885 |
| US-10947215-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | DHODH 2325/4885RAB9A 1486/4885MAPT 498/4885 |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | DHODH 2325/4885RAB9A 1486/4885MAPT 498/4885 |
| US-20190119252-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | DHODH 2325/4885RAB9A 1486/4885MAPT 498/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | DHODH 2325/4885RAB9A 1486/4885MAPT 498/4885 |
| US-20170066742-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | DHODH 2325/4885RAB9A 1486/4885MAPT 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.